drugset
drugset / Trial / NCT00400309

Safety of REPEVAX® Given One Month After REVAXIS®

NCT00400309 ↗

Phase 3 Completed 500 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupDouble-blindPrevention

Summary

Primary objective: * To describe the safety profile of a Tetanus, Diphtheria, Poliomyelitis and Pertussis vaccine (REPEVAX®) when administered as a pertussis booster 1 month after a Tetanus, Diphtheria, Poliomyelitis vaccine (REVAXIS®) as compared to the safety profile of REPEVAX® administered one month after Placebo. Secondary objectives: * To describe the safety of Td-IPV vaccine (REVAXIS®) or Placebo administered to healthy adults. * To describe the safety of TdaP-IPV vaccine (REPEVAX®) administered one month after Td-IPV vaccine (REVAXIS®) or one month after Placebo.

Timeline

Start
2006-06
Primary completion
2007-02
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject REPEVAX Vaccine — —
Subject REVAXIS® Vaccine — —

Indications

No indication recorded.